Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07874620
PHASE2

A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

Sponsor: Adneuris Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance to one of two cebranopadol dose regimens or matching placebo. The study will also evaluate pain, safety and tolerability, and cebranopadol pharmacokinetics.

Official title: A Randomized, Double-Blind, Multiple-Dose Study to Assess the Ability of Cebranopadol to Suppress Withdrawal Signs and Symptoms in Adults With Chronic Pain Who Are Physically Dependent on Opioids

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2026-09

Completion Date

2027-06

Last Updated

2026-10-19

Healthy Volunteers

No

Interventions

DRUG

Cebranopadol

Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.

DRUG

Cebranopadol

Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.

DRUG

Placebo

Administration orally twice daily on Day 1 and 2.

Locations (2)

001127

North Canton, Ohio, United States

00113

Houston, Texas, United States